244 related articles for article (PubMed ID: 22622363)
1. Vm24, a natural immunosuppressive peptide, potently and selectively blocks Kv1.3 potassium channels of human T cells.
Varga Z; Gurrola-Briones G; Papp F; Rodríguez de la Vega RC; Pedraza-Alva G; Tajhya RB; Gaspar R; Cardenas L; Rosenstein Y; Beeton C; Possani LD; Panyi G
Mol Pharmacol; 2012 Sep; 82(3):372-82. PubMed ID: 22622363
[TBL] [Abstract][Full Text] [Related]
2. K
Veytia-Bucheli JI; Jiménez-Vargas JM; Melchy-Pérez EI; Sandoval-Hernández MA; Possani LD; Rosenstein Y
Cell Commun Signal; 2018 Aug; 16(1):45. PubMed ID: 30107837
[TBL] [Abstract][Full Text] [Related]
3. Structure, function, and chemical synthesis of Vaejovis mexicanus peptide 24: a novel potent blocker of Kv1.3 potassium channels of human T lymphocytes.
Gurrola GB; Hernández-López RA; Rodríguez de la Vega RC; Varga Z; Batista CV; Salas-Castillo SP; Panyi G; del Río-Portilla F; Possani LD
Biochemistry; 2012 May; 51(19):4049-61. PubMed ID: 22540187
[TBL] [Abstract][Full Text] [Related]
4. sVmKTx, a transcriptome analysis-based synthetic peptide analogue of Vm24, inhibits Kv1.3 channels of human T cells with improved selectivity.
Csoti A; Del Carmen Nájera Meza R; Bogár F; Tajti G; Szanto TG; Varga Z; Gurrola GB; Tóth GK; Possani LD; Panyi G
Biochem Pharmacol; 2022 May; 199():115023. PubMed ID: 35358481
[TBL] [Abstract][Full Text] [Related]
5. Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomyelitis and inhibits T cell activation.
Beeton C; Barbaria J; Giraud P; Devaux J; Benoliel AM; Gola M; Sabatier JM; Bernard D; Crest M; Béraud E
J Immunol; 2001 Jan; 166(2):936-44. PubMed ID: 11145670
[TBL] [Abstract][Full Text] [Related]
6. The Kv1.3 channel blocker Vm24 enhances muscle glucose transporter 4 mobilization but does not reduce body-weight gain in diet-induced obese male rats.
Jaimes-Hoy L; Gurrola GB; Cisneros M; Joseph-Bravo P; Possani LD; Charli JL
Life Sci; 2017 Jul; 181():23-30. PubMed ID: 28549558
[TBL] [Abstract][Full Text] [Related]
7. The Scorpion Toxin Analogue BmKTX-D33H as a Potential Kv1.3 Channel-Selective Immunomodulator for Autoimmune Diseases.
Ye F; Hu Y; Yu W; Xie Z; Hu J; Cao Z; Li W; Wu Y
Toxins (Basel); 2016 Apr; 8(4):115. PubMed ID: 27104568
[TBL] [Abstract][Full Text] [Related]
8. The Kv1.3 K
Varga Z; Tajti G; Panyi G
Biol Futur; 2021 Mar; 72(1):75-83. PubMed ID: 34554500
[TBL] [Abstract][Full Text] [Related]
9. Targeting effector memory T cells with a selective peptide inhibitor of Kv1.3 channels for therapy of autoimmune diseases.
Beeton C; Pennington MW; Wulff H; Singh S; Nugent D; Crossley G; Khaytin I; Calabresi PA; Chen CY; Gutman GA; Chandy KG
Mol Pharmacol; 2005 Apr; 67(4):1369-81. PubMed ID: 15665253
[TBL] [Abstract][Full Text] [Related]
10. Immunosuppressive evidence of Tityus serrulatus toxins Ts6 and Ts15: insights of a novel K(+) channel pattern in T cells.
Pucca MB; Bertolini TB; Cerni FA; Bordon KC; Peigneur S; Tytgat J; Bonato VL; Arantes EC
Immunology; 2016 Feb; 147(2):240-50. PubMed ID: 26595158
[TBL] [Abstract][Full Text] [Related]
11. Prolonged immunomodulation in inflammatory arthritis using the selective Kv1.3 channel blocker HsTX1[R14A] and its PEGylated analog.
Tanner MR; Tajhya RB; Huq R; Gehrmann EJ; Rodarte KE; Atik MA; Norton RS; Pennington MW; Beeton C
Clin Immunol; 2017 Jul; 180():45-57. PubMed ID: 28389388
[TBL] [Abstract][Full Text] [Related]
12. Engineering a stable and selective peptide blocker of the Kv1.3 channel in T lymphocytes.
Pennington MW; Beeton C; Galea CA; Smith BJ; Chi V; Monaghan KP; Garcia A; Rangaraju S; Giuffrida A; Plank D; Crossley G; Nugent D; Khaytin I; Lefievre Y; Peshenko I; Dixon C; Chauhan S; Orzel A; Inoue T; Hu X; Moore RV; Norton RS; Chandy KG
Mol Pharmacol; 2009 Apr; 75(4):762-73. PubMed ID: 19122005
[TBL] [Abstract][Full Text] [Related]
13. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases.
Schmitz A; Sankaranarayanan A; Azam P; Schmidt-Lassen K; Homerick D; Hänsel W; Wulff H
Mol Pharmacol; 2005 Nov; 68(5):1254-70. PubMed ID: 16099841
[TBL] [Abstract][Full Text] [Related]
14. Targeting the ion channel Kv1.3 with scorpion venom peptides engineered for potency, selectivity, and half-life.
Edwards W; Fung-Leung WP; Huang C; Chi E; Wu N; Liu Y; Maher MP; Bonesteel R; Connor J; Fellows R; Garcia E; Lee J; Lu L; Ngo K; Scott B; Zhou H; Swanson RV; Wickenden AD
J Biol Chem; 2014 Aug; 289(33):22704-22714. PubMed ID: 24939846
[TBL] [Abstract][Full Text] [Related]
15. Anuroctoxin, a new scorpion toxin of the alpha-KTx 6 subfamily, is highly selective for Kv1.3 over IKCa1 ion channels of human T lymphocytes.
Bagdány M; Batista CV; Valdez-Cruz NA; Somodi S; Rodriguez de la Vega RC; Licea AF; Varga Z; Gáspár R; Possani LD; Panyi G
Mol Pharmacol; 2005 Apr; 67(4):1034-44. PubMed ID: 15615696
[TBL] [Abstract][Full Text] [Related]
16. Novel alpha-KTx peptides from the venom of the scorpion Centruroides elegans selectively blockade Kv1.3 over IKCa1 K+ channels of T cells.
Olamendi-Portugal T; Somodi S; Fernández JA; Zamudio FZ; Becerril B; Varga Z; Panyi G; Gáspár R; Possani LD
Toxicon; 2005 Sep; 46(4):418-29. PubMed ID: 16026809
[TBL] [Abstract][Full Text] [Related]
17. Peptide blockers of K
Chandy KG; Norton RS
Curr Opin Chem Biol; 2017 Jun; 38():97-107. PubMed ID: 28412597
[TBL] [Abstract][Full Text] [Related]
18. Solid phase synthesis, NMR structure determination of α-KTx3.8, its in silico docking to Kv1.x potassium channels, and electrophysiological analysis provide insights into toxin-channel selectivity.
Kohl B; Rothenberg I; Ali SA; Alam M; Seebohm G; Kalbacher H; Voelter W; Stoll R
Toxicon; 2015 Jul; 101():70-8. PubMed ID: 25953725
[TBL] [Abstract][Full Text] [Related]
19. Structural basis of a potent peptide inhibitor designed for Kv1.3 channel, a therapeutic target of autoimmune disease.
Han S; Yi H; Yin SJ; Chen ZY; Liu H; Cao ZJ; Wu YL; Li WX
J Biol Chem; 2008 Jul; 283(27):19058-65. PubMed ID: 18480054
[TBL] [Abstract][Full Text] [Related]
20. The Ca2+-activated K+ channel of intermediate conductance:a possible target for immune suppression.
Jensen BS; Hertz M; Christophersen P; Madsen LS
Expert Opin Ther Targets; 2002 Dec; 6(6):623-36. PubMed ID: 12472376
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]